Artivion, Inc. (NYSE:AORT) CEO James P. Mackin Sells 42,156 Shares

Artivion, Inc. (NYSE:AORT - Get Free Report) CEO James P. Mackin sold 42,156 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the completion of the transaction, the chief executive officer now directly owns 663,882 shares of the company's stock, valued at $18,130,617.42. This trade represents a 5.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Artivion Price Performance

Shares of AORT traded down $0.02 during mid-day trading on Friday, hitting $25.34. 568,539 shares of the company traded hands, compared to its average volume of 404,014. Artivion, Inc. has a one year low of $18.38 and a one year high of $32.33. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The business has a 50-day moving average of $29.51 and a 200 day moving average of $27.82. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -1,267.00 and a beta of 1.75.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. As a group, equities analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of Artivion

Several hedge funds have recently modified their holdings of the stock. Creative Planning grew its holdings in Artivion by 182.1% during the 3rd quarter. Creative Planning now owns 28,635 shares of the company's stock worth $762,000 after acquiring an additional 18,486 shares during the period. RiverPark Advisors LLC grew its holdings in Artivion by 151.6% during the 3rd quarter. RiverPark Advisors LLC now owns 5,387 shares of the company's stock worth $143,000 after acquiring an additional 3,246 shares during the period. Quest Partners LLC grew its holdings in Artivion by 2,481,700.0% during the 3rd quarter. Quest Partners LLC now owns 24,818 shares of the company's stock worth $661,000 after acquiring an additional 24,817 shares during the period. Intech Investment Management LLC grew its holdings in Artivion by 6.6% during the 3rd quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock worth $280,000 after acquiring an additional 653 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Artivion by 28.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company's stock worth $522,000 after acquiring an additional 4,295 shares during the period. 86.37% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Stifel Nicolaus dropped their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC decreased their price objective on shares of Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th. Finally, Oppenheimer upped their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.